In recent years, more and more real-world studies have revealed the obvious benefits of SGLT2 inhibitors against many respiratory diseases, such as chronic obstructive pulmonary disease (COPD) (Pradhan et al., 2022), pneumonia (Wu et al., 2022), obstructive airway disease (Au et al., 2023), pulmonary edema (Jeong et al., 2023), and respiratory failure (Jeong et al., 2023). The gene discussed is SLC5A2; the disease is chronic obstructive pulmonary disease.